by Sermonix Pharmaceuticals | Apr 29, 2024 | News
‘Significant and clinically meaningful’ results support Sermonix’s plans to study oral lasofoxifene’s impact on VVA in women with mBC being treated in ELAINE-3 trial COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a...
by Sermonix Pharmaceuticals | Apr 22, 2024 | News
COLUMBUS, Ohio, Apr. 22, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it will host a...
by Sermonix Pharmaceuticals | Feb 12, 2024 | News
COLUMBUS, Ohio, Feb. 12, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it is...
by Sermonix Pharmaceuticals | Jan 10, 2024 | News
Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rights Henlius to facilitate clinical development for the initiated Phase 3 MRCT (ELAINE-3) of...
by Sermonix Pharmaceuticals | Dec 12, 2023 | News
Most patients minimized or hid side effects from their health care providers for fear of negative perceptions, reduced treatment efficacy, or being taken off a drug or out of a clinical trial Sexual dysfunction was the most commonly cited side effect with a negative...
Recent Comments